NCT02197247 2021-07-12
Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC
AstraZeneca
Phase 1 Completed
AstraZeneca
GlaxoSmithKline
Eisai Inc.
Jiangsu HengRui Medicine Co., Ltd.
AstraZeneca
Hoffmann-La Roche
Bayer
Seagen Inc.